Fig. 1 · Structure

Documents & Downloads

Salubrinal

Cat. No. A12676 CAS 405060-95-9

eIF2α dephosphorylation inhibitor

Salubrinal is a cell-permeable, selective inhibitor of cellular phosphatase complexes that dephosphorylate eukaryotic translation initiation factor 2 subunit α (eIF2α). Protects cells from endoplasmic reticulum stress-induced apoptosis (EC50 ~ 15 μM).

In Stock

Publications for Salubrinal

1 publication citing this product

  1. Gregory R. Kardos, .et al. , Front Oncol, 2020, 10: 834 PMID: 32637352

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Salubrinal is used to modulate eIF2α phosphorylation. In Tg2576 primary cortical neurons, 50–80 μM salubrinal for 48 h increased the phospho-eIF2α/total eIF2α ratio, BACE1 protein and secreted amyloid-β40. These cellular results do not establish a direct molecular binding target or a purified-enzyme IC50. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
eIF2α (Cell-free assay)

Cellular Effect

Cell Line Activity Value Description Reference
PC-12 EC50 15 μM Cytoprotective activity on rat tunicamycin treated rat pheochromocytoma cell line PC12 from apoptosis induced by Endoplasmic reticulum stress [PMID: 16002288]

Salubrinal Research Summary

This section summarizes 3 in vitro studies and 3 in vivo studies of Salubrinal from 4 published references.

Salubrinal In Vitro Studies

In a melanoma cell panel, salubrinal combined with 40 μM 4E1RCat reduced 72-hour MTS viability more than either agent alone. The authors reported synergy across the tested melanoma lines, with less effect on FF2441 fibroblasts. Single-agent responses varied by cell line. [2]

Short-term salubrinal treatment reduced amyloid-β-induced injury in primary rat cortical neurons. At 6 h, this response occurred without increased eIF2α phosphorylation or reversal of BiP/PDI elevations. A separate 48-hour Tg2576-neuron experiment instead found increased BACE1 and secreted amyloid-β40, emphasizing the dependence of the response on model, exposure and endpoint. [3,1]

Salubrinal and 4E1RCat in melanoma cell viability

Cell-based study · Human melanoma C8161.Cl9 and MelJuSo (BRAF wild type), UACC 903, A375M and 1205 Lu (BRAF V600E); FF2441 normal human fibroblast comparator [2]

The combination reduced melanoma MTS viability more than either agent alone. Authors report synergy across melanoma lines; responses to single agents varied by cell line. FF2441 fibroblasts were less affected under these conditions.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MTS viability relative to controlQualitative outcome Combination reduced melanoma viability; less effect in FF2441 fibroblasts[2]
Combination indexQualitative outcome Authors report synergy for 10–50 μM salubrinal with 40 μM 4E1RCat in the melanoma lines[2]

Literature-Reported Treatment Conditions

Treatment concentration
Salubrinal 0–50 μM; combination paired with 40 μM 4E1RCat
Exposure duration
72 h
Method
MTS viability assay
Vehicle
DMSO
Co-treatment
4E1RCat; single-agent and DMSO comparator arms included
Reported limits
Figure 1 does not state replicate n; error bars are SEM. No IC50 was determined for this extraction.
Methods and source locations

Compound reported in the paper: Salubrinal; Compound label in the paper: Sal

Results concern the material and model reported by these authors. No Adooq lot validation, salt conversion or stereochemical equivalence is established.

Figure 1A–C; Determination of Cell Viability; Cell Line and Culture Conditions; first Results subsection

MTS viability relative to control: MTS absorbance; points represent average ± SEM. Qualitative extraction from viewed curves; exact percentages not digitized. — Figure 1A–C and caption; first Results subsection

Combination index: Chou–Talalay/CalcuSyn; authors define CI < 0.9 as synergistic, 0.9–1.1 additive and >1.1 antagonistic. No individual CI decimal inferred from scatter plots. — Figure 1 caption; Determination of Cell Viability

Short-term salubrinal in amyloid-challenged primary neurons

Cell-based study · Primary cortical neurons from E17 rat embryos; 14 DIV in Results 3.1 [3]

Salubrinal attenuated Aβ1-42-induced caspase-3 activation and TUNEL positivity and improved WST-8 viability. At 6 h it did not reverse Aβ-induced BiP/PDI elevations or increase eIF2α phosphorylation, limiting attribution of this short-term response to ER-stress inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cleaved caspase-3, TUNEL-positive neurons and WST-8 viabilityQualitative outcome Reduced Aβ-induced apoptosis markers and improved viability with salubrinal[3]
BiP, PDI and phospho-/total eIF2α at 6 hQualitative outcome No attenuation of Aβ-induced BiP/PDI elevations and no detected increase in eIF2α phosphorylation[3]

Literature-Reported Treatment Conditions

Treatment concentration
50 μM salubrinal for immunoblots/TUNEL; Figure 1C salubrinal titration 0–100 μM
Exposure duration
3 and 6 h caspase-3 assessment; 6 h TUNEL/WST-8 and ER-marker assessment
Method
Addition to neuronal culture
Co-treatment
Aβ1-42 25 μM; untreated, salubrinal-alone and Aβ-alone comparators for immunoblot/TUNEL
Reported limits
Vehicle is not stated in selected Methods. Figure 1 reports n = 3 but does not define the biological/technical replicate unit.
Methods and source locations

Compound reported in the paper: Salubrinal; Compound label in the paper: salubrinal

Results concern the material and model reported by these authors. No Adooq lot validation, salt conversion or stereochemical equivalence is established.

Figures 1A–C and 3A; Methods 2.1–2.4, 2.7, 2.9; Results 3.1 and 3.3

Cleaved caspase-3, TUNEL-positive neurons and WST-8 viability: Western blot with β-actin, TUNEL/DAPI and WST-8; n = 3, mean ± SEM under shared statistical methods. No exact bar values digitized. — Figure 1A–C and caption; Results 3.1

BiP, PDI and phospho-/total eIF2α at 6 h: Immunoblot; Figure 3A representative blots, β-actin loading control. No formal equivalence test or exact fold change reported for this panel. — Figure 3A and caption; Results 3.3

Longer salubrinal exposure increases BACE1 and secreted amyloid-β

Cell-based study · Primary cortical Tg2576 mouse neurons expressing human APPsw; E15.5 embryos, 7 DIV before treatment [1]

At 48 h, salubrinal increased phospho-eIF2α/total eIF2α and endogenous BACE1, with increased conditioned-medium human Aβ40. This is limiting evidence for interpreting sustained eIF2α phosphorylation as uniformly protective.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Phospho-eIF2α/total eIF2α and BACE1 proteinQualitative outcome Both increased at 50 and 80 μM compared with control[1]
Secreted human Aβ40 per total cellular proteinng Aβ40/mg protein Control: 13.25 ± 0.33; 50 μM: 15.88 ± 0.63 (p < 0.05); 80 μM: 27.19 ± 1.61 (p < 0.01) ng Aβ40/mg protein[1]

Literature-Reported Treatment Conditions

Treatment concentration
50 or 80 μM
Exposure duration
48 h
Method
Added to glucose-containing neuronal culture medium
Reported limits
Selected text does not specify the solvent/vehicle for salubrinal. Control is normal glucose-containing medium. n = 4 in Figure 4D–F; replicate unit not further defined there.
Methods and source locations

Compound reported in the paper: Salubrinal; Compound label in the paper: salubrinal

Results concern the material and model reported by these authors. No Adooq lot validation, salt conversion or stereochemical equivalence is established.

Figure 4D–F and caption; Selective Inhibition of eIF2α Dephosphorylation Increases BACE1 Level and Aβ production in Tg2576 Primary Neurons; Neuronal Cultures; Immunoblot Analysis; Human Aβ40 ELISA; Statistical analysis

Phospho-eIF2α/total eIF2α and BACE1 protein: Immunoblot; BACE1 normalized to β-actin and phospho-eIF2α to total eIF2α; n = 4, mean ± SEM; UV-treated 293 lysate used as phospho-eIF2α positive control. No exact fold changes digitized. — Figure 4D/E and caption

Secreted human Aβ40 per total cellular protein: Human Aβ40-specific ELISA of conditioned medium; n = 4, mean ± SEM; shared methods specify two-tailed t-test versus control. Exact values taken from Results prose, with figure inspected. — Figure 4F; Results subsection Selective Inhibition of eIF2α Dephosphorylation Increases BACE1 Level and Aβ production in Tg2576 Primary Neurons

Salubrinal In Vivo Studies

In a UACC 903 melanoma xenograft dose-ranging experiment, salubrinal at 1 mg/kg combined with 4E1RCat at 10 mg/kg gave the lowest tumor-volume response among the tested combinations at the 20-day assessment. This was a combination result in a small mouse experiment with two tumors per mouse. [2]

In two separate, matched SOD1G93A mouse efficacy studies, daily intraperitoneal salubrinal at 5 or 15 mg/kg did not improve overall neurological progression, disease onset or survival. The 5 mg/kg cohort showed a small improvement in body-weight maintenance (p = 0.03), without a survival benefit. [4]

Salubrinal combination in a UACC 903 xenograft dose study

Animal study · UACC 903 human melanoma xenografts in 4–6-week-old female Athymic-Foxn1nu nude mice [2]

In the dose-ranging experiment, the 1 mg/kg salubrinal plus 10 mg/kg 4E1RCat combination produced the lowest tumor-volume response at the reported 20-day assessment. Single-agent salubrinal and 4E1RCat groups were included; the finding is a combination outcome.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volume at 20-day assessmentQualitative outcome Lowest plotted tumor volume with 1:10 mg/kg salubrinal:4E1RCat among tested combinations[2]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
On alternate days
Treatment course
Treatment began 6–8 days after tumor implantation; shared methods specify 3–4 weeks
Vehicle
DMSO; composition not specified
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Salubrinal plus 4E1RCat
Salubrinal 1 mg/kg + 4E1RCat 10 mg/kg
DMSO vehicle; single-agent groups displayed but their effects are not the adopted comparisonLowest tumor-volume response among tested dose combinations at 20 days; no exact numerical volume extracted[2]
Salubrinal plus 4E1RCat
Model: UACC 903 human melanoma xenografts in 4–6-week-old female Athymic-Foxn1nu nude mice
Reported limits: Shared methods: 4 mice/group, 2 tumors/mouse; Figure 2A separate n not specified.
Methods and source locations

Compound reported in the paper: Salubrinal; Compound label in the paper: Sal

Results concern the material and model reported by these authors. No Adooq lot validation, salt conversion or stereochemical equivalence is established.

Figure 2A and caption; Animal Studies; Combination Sal and 4E1RCat Decreased Melanoma Xenograft Tumor Growth

Tumor volume at 20-day assessment: Viewed Figure 2A; bars average ± SEM. No curve/bar values digitized; tumors within a mouse are not independent animals. — Figure 2A; corresponding Results subsection

Salubrinal plus 4E1RCat · Figure 2A; Animal Studies; corresponding Results

Salubrinal 5 mg/kg in a separate SOD1G93A efficacy cohort

Animal study · High-copy SOD1G93A transgenic mice on C57BL6-SJL background; age-/litter-matched and sex-balanced treatment and vehicle groups [4]

Chronic treatment did not improve overall neurological disease progression, disease onset or survival compared with the matched vehicle cohort. Body-weight maintenance improved (p = 0.03).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Neurological progression, disease onset, survival and body weightQualitative outcome No overall benefit in progression, onset or survival. Body-weight maintenance improved (p = 0.03).[4]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Once daily
Treatment course
From approximately 50 ± 3 days of age until humane endpoint (approximately 70–80 days)
Vehicle
2.5% NMP / 2.5% Kolliphor HS15 / 95% filtered tap water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Salubrinal 5 mg/kgMatched vehicle, n = 32; salubrinal, n = 32; both sex-balancedNo overall improvement in neurological progression, onset or survival. Body-weight maintenance improved (p = 0.03).[4]
Salubrinal 5 mg/kg
Model: High-copy SOD1G93A transgenic mice on C57BL6-SJL background; age-/litter-matched and sex-balanced treatment and vehicle groups
Reported limits: Group allocation is age-/litter-matched and sex-balanced. Randomization and blinding are not established in the selected survival-methods text.
Methods and source locations

Compound reported in the paper: Salubrinal; Compound label in the paper: salubrinal

Results concern the material and model reported by these authors. No Adooq lot validation, salt conversion or stereochemical equivalence is established.

Figure 8 and caption; Table 1; Salubrinal survival efficacy studies; Animals; Drug survival efficacy studies; Drug formulations; Statistical analyses

Neurological progression, disease onset, survival and body weight: Each independently conducted cohort: 32 drug-treated and 32 vehicle-treated mice; neurological scores analyzed by ordinal logistic regression; time-to-event analyses by Kaplan–Meier and Cox methods. No survival-day estimates read from curves. — Figure 8; Table 1; Salubrinal survival efficacy studies

Salubrinal 5 mg/kg · Figure 8 and caption; Table 1; Salubrinal survival efficacy studies; Animals; Drug survival efficacy studies; Drug formulations; Statistical analyses

Salubrinal 15 mg/kg in a separate SOD1G93A efficacy cohort

Animal study · High-copy SOD1G93A transgenic mice on C57BL6-SJL background; age-/litter-matched and sex-balanced treatment and vehicle groups [4]

Chronic treatment did not improve overall neurological disease progression, disease onset or survival compared with the matched vehicle cohort. No overall body-weight improvement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Neurological progression, disease onset, survival and body weightQualitative outcome No overall benefit in progression, onset or survival. No overall body-weight improvement.[4]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Once daily
Treatment course
From approximately 50 ± 3 days of age until humane endpoint (approximately 70–80 days)
Vehicle
5% NMP / 5% Kolliphor HS15 / 90% filtered tap water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Salubrinal 15 mg/kgMatched vehicle, n = 32; salubrinal, n = 32; both sex-balancedNo overall improvement in neurological progression, onset or survival. No overall body-weight improvement.[4]
Salubrinal 15 mg/kg
Model: High-copy SOD1G93A transgenic mice on C57BL6-SJL background; age-/litter-matched and sex-balanced treatment and vehicle groups
Reported limits: Group allocation is age-/litter-matched and sex-balanced. Randomization and blinding are not established in the selected survival-methods text.
Methods and source locations

Compound reported in the paper: Salubrinal; Compound label in the paper: salubrinal

Results concern the material and model reported by these authors. No Adooq lot validation, salt conversion or stereochemical equivalence is established.

Figure 9 and caption; Table 1; Salubrinal survival efficacy studies; Animals; Drug survival efficacy studies; Drug formulations; Statistical analyses

Neurological progression, disease onset, survival and body weight: Each independently conducted cohort: 32 drug-treated and 32 vehicle-treated mice; neurological scores analyzed by ordinal logistic regression; time-to-event analyses by Kaplan–Meier and Cox methods. No survival-day estimates read from curves. — Figure 9; Table 1; Salubrinal survival efficacy studies

Salubrinal 15 mg/kg · Figure 9 and caption; Table 1; Salubrinal survival efficacy studies; Animals; Drug survival efficacy studies; Drug formulations; Statistical analyses

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 405060-95-9
Applications

eIF2α dephosphorylation inhibitor

Formula C21H17N4OSCl3
Molecular Weight 479.81
SMILES
C1=CC=C(C=C1)/C=C/C(=O)NC(C(Cl)(Cl)Cl)NC(=S)NC2=CC=CC3=C2N=CC=C3

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 86 mg/mL (179.23 mM)
Water Insoluble
Ethanol 2 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Salubrinal Research References

  1. [1] O'Connor T, Sadleir KR, Maus E, et al. Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis Neuron (2008). PMID: 19109907 DOI: 10.1016/j.neuron.2008.10.047 Source material
  2. [2] Kardos GR, Gowda R, Dinavahi SS, et al. Salubrinal in Combination With 4E1RCat Synergistically Impairs Melanoma Development by Disrupting the Protein Synthetic Machinery Frontiers in Oncology (2020). PMID: 32637352 DOI: 10.3389/fonc.2020.00834 Source material
  3. [3] Huang X, Chen Y, Zhang H, et al. Salubrinal attenuates β-amyloid-induced neuronal death and microglial activation by inhibition of the NF-κB pathway Neurobiology of Aging (2012). PMID: 22056200 DOI: 10.1016/j.neurobiolaging.2011.10.007 Source material
  4. [4] Vieira FG, Tassinari VR, Kidd JD, et al. PERK modulation, with GSK2606414, Sephin1 or salubrinal, failed to produce therapeutic benefits in the SOD1G93A mouse model of ALS PLOS ONE (2024). PMID: 38359044 DOI: 10.1371/journal.pone.0292190 Source material

Publications

1 publication citing this product

  1. Gregory R. Kardos, .et al. , Front Oncol, 2020, 10: 834 PMID: 32637352

Added to your cart

View Cart Checkout
Loading...